The trial explores opportunities to further improve outcomes in patients with impaired left ventricular function after myocardial infarction, which may broaden the indication for the use of SGLT2 inhibitor trials in patients with acute myocardial infarction are listed in Table 2. Here, SLC5A2 is linked to myocardial infarction.